Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H21FN2O |
Molecular Weight | 324.3927 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCC[C@]1(c2ccc(cc2)F)c3ccc(cc3CO1)C#N
InChI
InChIKey=WSEQXVZVJXJVFP-FQEVSTJZSA-N
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1
Molecular Formula | C20H21FN2O |
Molecular Weight | 324.3927 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Escitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). Escitalopram, also known by the brand names Lexapro and Cipralex among others, is an antidepressant. The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to
be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition
of CNS neuronal reuptake of serotonin (5-HT). In vitro and in vivo studies in animals suggest that escitalopram is
a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine and dopamine
neuronal reuptake. Escitalopram is at least 100-fold more potent than the R-enantiomer with respect to inhibition
of 5-HT reuptake and inhibition of 5-HT neuronal firing rate. LEXAPRO (escitalopram) is indicated for the treatment of major depressive disorder and generalized anxiety disorder .
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24045971 |
2.6 µM [IC50] | ||
1.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LEXAPRO Approved UseINDICATIONS & USAGE Escitalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for:
Acute and Maintenance Treatment of Major Depressive Disorder (MDD) in adults and adolescents aged 12 to 17 years (1.1) Acute Treatment of Generalized Anxiety Disorder (GAD) in adults (1.2) Escitalopram tablets USP are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age. Launch Date1.02928318E12 |
|||
Primary | LEXAPRO Approved UseLexapro® is a selective serotonin reuptake inhibitor (SSRI) indicated for:
Acute and Maintenance Treatment of Major Depressive
Disorder (MDD) in adults and adolescents aged 12-17 years (1.1)
Acute Treatment of Generalized Anxiety Disorder (GAD) in adults (1.2) Launch Date1.02928318E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
63.4 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16291715 |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ESCITALOPRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
198.4 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16291715 |
30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ESCITALOPRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
58.6 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16291715 |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ESCITALOPRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
58 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16291715 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ESCITALOPRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1109 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16291715 |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ESCITALOPRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3391 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16291715 |
30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ESCITALOPRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1102 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16291715 |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ESCITALOPRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1964 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16291715 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ESCITALOPRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
29 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16291715 |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ESCITALOPRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
32.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16291715 |
30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ESCITALOPRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
26.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16291715 |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ESCITALOPRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
26.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16291715 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ESCITALOPRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
44% |
ESCITALOPRAM plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Disc. AE: Coma, Dizziness... AEs leading to discontinuation/dose reduction: Coma (grade 3-4, 1 patient) Sources: Dizziness (grade 1-2, 2 patients) Restlessness (grade 1-2, 2 patients) Agitation (grade 3-4, 4 patients) Convulsion (grade 3-4, 1 patient) Tremor (grade 1-2, 8 patients) Mydriasis (grade 1-2, 3 patients) Tachycardia (grade 1-2, 7 patients) Change in ECG (grade 1-2, 4 patients) Change in ECG (grade 3-4, 1 patient) Nausea (grade 1-2, 4 patients) Vomiting (grade 1-2, 8 patients) Vomiting (grade 3-4, 1 patient) Intestinal atony (grade 3-4, 1 patient) Urinary retention (grade 3-4, 1 patient) Somnolence (grade 1-2, 25 patients) |
140 mg single, oral (median) Overdose |
unknown, 18 - 36 years n = 46 Health Status: unknown Age Group: 18 - 36 years Sex: M+F Population Size: 46 Sources: |
Disc. AE: Clonus, Clonus... AEs leading to discontinuation/dose reduction: Clonus (12 patients) Sources: Clonus (2 patients) Hyperreflexia (21 patient) Myoclonus (3 patients) Eyelid myoclonus (2 patients) Hunter's syndrome (7 patients) |
140 mg single, oral (median) Overdose Dose: 140 mg Route: oral Route: single Dose: 140 mg Co-administed with:: coingested drugs Sources: |
unknown, 24 - 43 years n = 33 Health Status: unknown Age Group: 24 - 43 years Sex: M+F Population Size: 33 Sources: |
Disc. AE: Clonus, Hyperreflexia... AEs leading to discontinuation/dose reduction: Clonus (3 patients) Sources: Hyperreflexia (9 patients) Eyelid myoclonus (2 patients) Hunter's syndrome (1 patient) |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 46.2 years n = 4185 Health Status: unhealthy Condition: Psychiatric diagnoses Age Group: 46.2 years Sex: M+F Population Size: 4185 Sources: |
Disc. AE: Coronary heart disease... AEs leading to discontinuation/dose reduction: Coronary heart disease (10.7%) Sources: |
33.8 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 33.8 mg, 1 times / day Route: oral Route: steady Dose: 33.8 mg, 1 times / day Sources: |
unhealthy, adult n = 64 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 64 Sources: |
Other AEs: Dry mouth, Sexual desire decreased... Other AEs: Dry mouth (8 patients) Sources: Sexual desire decreased (21 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | grade 1-2, 2 patients Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Restlessness | grade 1-2, 2 patients Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Somnolence | grade 1-2, 25 patients Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Mydriasis | grade 1-2, 3 patients Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Change in ECG | grade 1-2, 4 patients Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Nausea | grade 1-2, 4 patients Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Tachycardia | grade 1-2, 7 patients Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Tremor | grade 1-2, 8 patients Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Vomiting | grade 1-2, 8 patients Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Change in ECG | grade 3-4, 1 patient Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Coma | grade 3-4, 1 patient Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Convulsion | grade 3-4, 1 patient Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Intestinal atony | grade 3-4, 1 patient Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Urinary retention | grade 3-4, 1 patient Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Vomiting | grade 3-4, 1 patient Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Agitation | grade 3-4, 4 patients Disc. AE |
332 mg single, oral (mean) Overdose |
unknown, 16 - 84 years n = 63 Health Status: unknown Age Group: 16 - 84 years Sex: M+F Population Size: 63 Sources: |
Clonus | 12 patients Disc. AE |
140 mg single, oral (median) Overdose |
unknown, 18 - 36 years n = 46 Health Status: unknown Age Group: 18 - 36 years Sex: M+F Population Size: 46 Sources: |
Clonus | 2 patients Disc. AE |
140 mg single, oral (median) Overdose |
unknown, 18 - 36 years n = 46 Health Status: unknown Age Group: 18 - 36 years Sex: M+F Population Size: 46 Sources: |
Eyelid myoclonus | 2 patients Disc. AE |
140 mg single, oral (median) Overdose |
unknown, 18 - 36 years n = 46 Health Status: unknown Age Group: 18 - 36 years Sex: M+F Population Size: 46 Sources: |
Hyperreflexia | 21 patient Disc. AE |
140 mg single, oral (median) Overdose |
unknown, 18 - 36 years n = 46 Health Status: unknown Age Group: 18 - 36 years Sex: M+F Population Size: 46 Sources: |
Myoclonus | 3 patients Disc. AE |
140 mg single, oral (median) Overdose |
unknown, 18 - 36 years n = 46 Health Status: unknown Age Group: 18 - 36 years Sex: M+F Population Size: 46 Sources: |
Hunter's syndrome | 7 patients Disc. AE |
140 mg single, oral (median) Overdose |
unknown, 18 - 36 years n = 46 Health Status: unknown Age Group: 18 - 36 years Sex: M+F Population Size: 46 Sources: |
Hunter's syndrome | 1 patient Disc. AE |
140 mg single, oral (median) Overdose Dose: 140 mg Route: oral Route: single Dose: 140 mg Co-administed with:: coingested drugs Sources: |
unknown, 24 - 43 years n = 33 Health Status: unknown Age Group: 24 - 43 years Sex: M+F Population Size: 33 Sources: |
Eyelid myoclonus | 2 patients Disc. AE |
140 mg single, oral (median) Overdose Dose: 140 mg Route: oral Route: single Dose: 140 mg Co-administed with:: coingested drugs Sources: |
unknown, 24 - 43 years n = 33 Health Status: unknown Age Group: 24 - 43 years Sex: M+F Population Size: 33 Sources: |
Clonus | 3 patients Disc. AE |
140 mg single, oral (median) Overdose Dose: 140 mg Route: oral Route: single Dose: 140 mg Co-administed with:: coingested drugs Sources: |
unknown, 24 - 43 years n = 33 Health Status: unknown Age Group: 24 - 43 years Sex: M+F Population Size: 33 Sources: |
Hyperreflexia | 9 patients Disc. AE |
140 mg single, oral (median) Overdose Dose: 140 mg Route: oral Route: single Dose: 140 mg Co-administed with:: coingested drugs Sources: |
unknown, 24 - 43 years n = 33 Health Status: unknown Age Group: 24 - 43 years Sex: M+F Population Size: 33 Sources: |
Coronary heart disease | 10.7% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 46.2 years n = 4185 Health Status: unhealthy Condition: Psychiatric diagnoses Age Group: 46.2 years Sex: M+F Population Size: 4185 Sources: |
Sexual desire decreased | 21 patient | 33.8 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 33.8 mg, 1 times / day Route: oral Route: steady Dose: 33.8 mg, 1 times / day Sources: |
unhealthy, adult n = 64 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 64 Sources: |
Dry mouth | 8 patients | 33.8 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 33.8 mg, 1 times / day Route: oral Route: steady Dose: 33.8 mg, 1 times / day Sources: |
unhealthy, adult n = 64 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 64 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_BioPharmr.pdf Page: 70.0 |
yes [Km 29 uM] | yes (co-administration study) Comment: coadministration of escitalopram with desipramine resulted in a 50% increase in desipramine concentraitons Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_BioPharmr.pdf Page: 70.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_BioPharmr.pdf Page: 70.0 |
yes [Km 588 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_BioPharmr.pdf Page: 70.0 |
yes [Km 69 uM] | |||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Pharmr_P1.pdf Page: 16.0 |
PubMed
Title | Date | PubMed |
---|---|---|
New single-isomer compounds on the horizon. | 2002 Apr |
|
Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. | 2002 Apr |
|
Escitalopram: a second-generation SSRI. | 2002 Apr |
|
Great expectations in stereochemistry: focus on antidepressants. | 2002 Apr |
|
A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. | 2003 |
|
Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions. | 2004 |
|
A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. | 2004 |
|
Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. | 2004 |
|
Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. | 2004 |
|
New formulations of existing antidepressants: advantages in the management of depression. | 2004 |
|
A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. | 2004 |
|
Spotlight on the pharmacoeconomics of escitalopram in depression. | 2004 |
|
Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique. | 2004 Apr |
|
"Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review. | 2004 Aug |
|
Gateways to clinical trials. | 2004 Dec |
|
A case of hyponatremia associated with escitalopram. | 2004 Dec |
|
Selective binding of 2-[125I]iodo-nisoxetine to norepinephrine transporters in the brain. | 2004 Jul |
|
Escitalopram versus citalopram: the surprising role of the R-enantiomer. | 2004 Jul |
|
Gateways to clinical trials. | 2004 Jul-Aug |
|
Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. | 2004 Jun |
|
Escitalopram in trichotillomania. | 2004 Jun |
|
Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors. | 2004 Jun |
|
[Escitalopram--second generation of serotonin transporter inhibitors?]. | 2004 Mar-Apr |
|
[Escitalopram: a chiral agent for treatment of depression]. | 2004 May |
|
Antidepressant-associated mania with escitalopram. | 2004 Nov |
|
Liquid chromatography--electrospray ionisation mass spectrometry method for the determination of escitalopram in human plasma and its application in bioequivalence study. | 2004 Nov 25 |
|
Venous thromboembolism and escitalopram. | 2004 Nov-Dec |
|
Gateways to clinical trials. | 2004 Oct |
|
The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. | 2004 Oct 22 |
|
A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. | 2004 Sep |
|
Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. | 2004 Sep |
|
Evidence based review of escitalopram in treating major depressive disorder in primary care. | 2004 Sep |
|
Reformulation of consumer health queries with professional terminology: a pilot study. | 2004 Sep 3 |
|
Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. | 2005 |
|
Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. | 2005 |
|
Generalised anxiety disorder in elderly patients : epidemiology, diagnosis and treatment options. | 2005 |
|
The safety of newer antidepressants in pregnancy and breastfeeding. | 2005 |
|
An open-label trial of escitalopram in pervasive developmental disorders. | 2005 Apr |
|
Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. | 2005 Dec |
|
A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium. | 2005 Jan |
|
Escitalopram intoxication. | 2005 Jan |
|
Quetiapine-induced weight gain and escitalopram. | 2005 Jan |
|
Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV. | 2005 Jan |
|
Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. | 2005 Jul |
|
Evidence-based pharmacotherapy of Generalized Anxiety Disorder. | 2005 Jun |
|
Treatment of Raynaud's phenomenon with escitalopram. | 2005 Jun |
|
Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. | 2005 Mar |
|
The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. | 2005 Mar |
|
Escitalopram and suicidality in adult depression and anxiety. | 2005 May |
|
Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. | 2005 May |
Patents
Sample Use Guides
Lexapro (escitalopram) should generally be administered once daily, morning
or evening with or without food.
Initial: 10 mg once daily
Recommended: 10 mg once daily
Maximum: 20 mg once daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24045971
Escitalopram blocked human hERG currents expressed in human embryonic kidney cells in a concentration-dependent manner with an IC50 value of 2.6 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:08:15 UTC 2021
by
admin
on
Fri Jun 25 21:08:15 UTC 2021
|
Record UNII |
4O4S742ANY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
||
|
WHO-ATC |
N06AB10
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
||
|
LIVERTOX |
368
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
||
|
NCI_THESAURUS |
C94725
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
||
|
NDF-RT |
N0000175696
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
||
|
NDF-RT |
N0000000109
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
||
|
WHO-VATC |
QN06AB10
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1053
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
CHEMBL1508
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
Escitalopram
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
DB01175
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
SUB44650
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
ESCITALOPRAM
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
321988
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | RxNorm | ||
|
4O4S742ANY
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
SUB16425MIG
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
7953
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
C61754
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
146570
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
7177
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
128196-01-0
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
128196-01-0
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | |||
|
M3587
Created by
admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
RACEMATE -> ENANTIOMER | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
The principal metabolite of escitalopram is Sdemethylcitalopram
(S-DCT), which may be further
metabolized to S-didemethylcitalopram (S-DDCT) in
small quantities.
|
||
|
METABOLITE INACTIVE -> PARENT |
The principal metabolite of escitalopram is Sdemethylcitalopram
(S-DCT), which may be further
metabolized to S-didemethylcitalopram (S-DDCT) in
small quantities.
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
ESCITALOPRAM OXALATE (ELDERLY) PHARMACOKINETIC PHARMACOKINETIC |
|
||
BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
|
|||